In vitro study on the immunomodulatory effects of differently functionalized silver nanoparticles on human peripheral blood mononuclear cells.
Activation
Flow cytometry
Human peripheral blood mononuclear cells
Particle surface functionalization
Surface cell markers
Journal
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
ISSN: 1432-1327
Titre abrégé: J Biol Inorg Chem
Pays: Germany
ID NLM: 9616326
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
06
04
2021
accepted:
28
08
2021
pubmed:
4
9
2021
medline:
14
1
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
The interaction of silver nanoparticles (AgNPs) with the immune system has not yet been sufficiently elucidated even though they belong to the most investigated and exploited group of nanomaterials. This study aimed to evaluate immunomodulatory effect of four different AgNPs on human peripheral blood mononuclear cells (hPBMCs). Fresh hPBMCs were exposed to the small sized (~ 10 nm) AgNPs immediately after isolation from the whole blood of healthy volunteers. The study considered coating-, time- and dose-dependent response of hPBMSc and stimulation of both early and intermediate activation of lymphocytes and monocytes using flow cytometry. The AgNPs differed in surface charge and were stabilised with polyvinyl pyrrolidone (PVP), poly-L-lysine (PLL), bis(2-ethylhexyl) sulfosuccinate sodium (AOT) or blood serum albumin (BSA). Response of hPBMCs to coating agents and ionic Ag form was evaluated to distinguish their effect from the AgNPs action as they may be released from the nanosurface. There was no significant effect of any tested AgNPs on relative count of hPBMCs subpopulations. The T-cells and monocytes were not activated after treatment with AgNPs, but the highest concentration of PLL- and BSA-AgNPs decreased density of CD4 and CD8 markers on T-helper and T-cytotoxic cells, respectively. The same AgNPs activated B- and NK-cells. Ionic Ag activated T-, B- and NK-cells, but at very higher concentration, whereas only PLL exhibited immunomodulatory activity. This study evidenced immunomodulatory activity of AgNPs that may be fine-tuned by the design of their surface functionalization.
Identifiants
pubmed: 34476609
doi: 10.1007/s00775-021-01898-0
pii: 10.1007/s00775-021-01898-0
pmc: PMC8412400
doi:
Substances chimiques
Silver
3M4G523W1G
Povidone
FZ989GH94E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
817-831Informations de copyright
© 2021. Society for Biological Inorganic Chemistry (SBIC).
Références
Ninan N, Goswami N, Vasilev K (2020) The impact of engineered silver nanomaterials on the immune system. Nanomaterials 10(5):967
doi: 10.3390/nano10050967
Klippstein R, Fernandez-Montesinos R, Castillo PM, Zaderenko AP, Pozo Perez D (2010) Silver nanoparticles interactions with the immune system: implications for health and disease. In: Pozo Perez D (ed) Silver nanoparticles, IntechOpen, London, p 309–324. Available from: https://www.intechopen.com/chapters/9728 .
Luo YH, Chang LW, Lin P (2015) Metal-based nanoparticles and the immune system: activation, inflammation, and potential applications. Biomed Res Int 2015:143720
pubmed: 26125021
pmcid: 4466342
AL-Rahman A, Munaf R, Ibrahim SR, AL-Aqidi I (2016) The effect of silver nanoparticles on cellular and humoral immunity of mice in vivo and in vitro. Iraqi J Biotech 15(2):21–29
Kononenko V, Narat M, Drobne D (2015) Nanoparticle interaction with the immune system. Arh Hig Rada Toksikol 66(2):97–108
doi: 10.1515/aiht-2015-66-2582
Dobrovolskaia MA, Shurin M, Shvedova AA (2016) Current understanding of interactions between nanoparticles and the immune system. Toxicol Appl 299:78–89
doi: 10.1016/j.taap.2015.12.022
Kubo AL, Capjak I, Vinković Vrček I, Bondarenko OM, Kurvet I, Vija H, Ivask A, Kasemets K, Kahru A (2018) Antimicrobial potency of differently coated 10 and 50 nm silver nanoparticles against clinically relevant bacteria Escherichia coli and Staphylococcus aureus. Colloids Surf B Biointerfaces 170:401–410
doi: 10.1016/j.colsurfb.2018.06.027
Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R (2009) Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug Chem 20:1497–1502
doi: 10.1021/bc900215b
Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ (2005) Interactions of silver nanoparticles with HIV-1. J Nanobiotechnol 3:6
doi: 10.1186/1477-3155-3-6
Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP (2014) Nanoparticle vaccines. Vaccine 32:327–337
doi: 10.1016/j.vaccine.2013.11.069
Wei L, Lu J, Xu H, Patel A, Chen Z-S, Chen G (2015) Silver nanoparticles: synthesis, properties, and therapeutic applications. Drug Discov Today 20(5):595–601
doi: 10.1016/j.drudis.2014.11.014
Minigo G, Scholzen A, Tang CK, Hanley JC, Kalkanidis M, Pietersz GA, Apostolopoulos V, Plebanski M (2007) Poly-L-lysine-coated nanoparticles: a potent delivery system to enchance DNA vaccine efficacy. Vaccine 25(7):1316–1327
doi: 10.1016/j.vaccine.2006.09.086
Chakraborty B, Pal R, Ali M, Singh LM, Shahidur Rahman D, Kumar Ghosh S, Sengupta M (2016) Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma. Cell Mol Immunol 13(2):191–205
doi: 10.1038/cmi.2015.05
Guo D, Zhu L, Huang Z, Zhou H, Ge Y, Ma W, Wu J, Zhang X, Zhou X, Zhang Y, Zhao Y, Gu N (2013) Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions. Biomaterials. https://doi.org/10.1016/j.biomaterials.2013.07.015
doi: 10.1016/j.biomaterials.2013.07.015
pubmed: 24373420
pmcid: 8086596
Vinhas R, Mendes R, Fernandes AR, Baptista PV (2017) Nanoparticles-emerging potential for managing leukemia and lymphoma. Front Bioeng Biotechnol 5:79
doi: 10.3389/fbioe.2017.00079
Houshmand M, Garello F, Circosta P, Stefania R, Aime S, Saglio G, Giachino C (2020) Nanocarriers as magic bullets in the treatment of leukemia. Nanomaterials (Basel) 10(2):276
doi: 10.3390/nano10020276
Vuković B, Milić M, Dobrošević B, Milić M, Ilić K, Pavičić I, Šerić V, Vinković Vrček I (2020) Surface stabilization affects toxicity of silver nanoparticles in human peripheral blood mononuclear cells. Nanomaterials (Basel) 10(7):1390
doi: 10.3390/nano10071390
Nielsen SD, Afzelius P, Ersboll AK, Nielsen JP, Hansen J-ES (1998) Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients. Clin Exp Immunol 114:66–72
doi: 10.1046/j.1365-2249.1998.00685.x
Jurašin DD, Ćurlin M, Capjak I, Crnković T, Lovrić M, Babič M, Horák D, Vinković Vrček I, Gajović S (2016) Surface coating affects behaviour of metallic nanoparticles in a biological environment. Bellstein J Nanotechnol 7(1):246–262
doi: 10.3762/bjnano.7.23
Milić M, Leitinger G, Pavičić I, Zebić Avdičević M, Dobrović S, Goessler W, Vinković Vrček I (2014) Cellular uptake and toxicity effects of silver nanoparticles in mammalian kidney cells. J Appl Toxicol 35(6):581–592
doi: 10.1002/jat.3081
Shin SH, Ye MK, Kim HS, Kang HS (2007) The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells. Int Immunopharmacol 7:1813–1818
doi: 10.1016/j.intimp.2007.08.025
Alsaleh NB, Minarchick VC, Mendoza RP, Sharma B, Podila R, Brown JM (2019) Silver nanoparticle immunomodulatory potential in absence of direct cytotoxicity in RAW 264.7 macrophages and MPRO 2.1 neutrophils. J Immunotoxicol 16(1):63–73
doi: 10.1080/1547691X.2019.1588928
Zelikoff J, Willis D, Degheidy H, Zhang Q, Umbreit T, Goering P (2013) Immune cell profiles in response to silver nanoparticles associated with medical devices. J Immunol 190(1):202.1
Lo YC, Eddin MA, Powell JD (2013) Selective activation of antigen-experienced T cells by anti-CD3 constrained on nanoparticles. J Immunol 191:5107–5114
doi: 10.4049/jimmunol.1301433
Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Brownlie D, Cuapio A, Ask EH, Hull RM, Haroun-Izquierdo A, Schaffer M, Klingström J, Folkesson E, Buggert M, Sandberg JK, Eriksson LI, Rooyackers O, Ljunggren HG, Malmberg KJ, Michaëlsson J, Marquardt N, Hammer Q, Strålin K, Björkström NK, Karolinska COVID-19 Study Group (2020) Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol 5(50):6832
doi: 10.1126/sciimmunol.abd6832
Temchura VV, Kozlova D, Sokolova V, Überla K, Epple M (2014) Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen. Biomaterials 35(23):6098–6105
doi: 10.1016/j.biomaterials.2014.04.010
Appleby LJ, Nausch N, Midzi N, Mduluza T, Allen JE, Mutapi F (2013) Sources of heterogenity in human monocyte subsets. Immunol Lett 152(1):32–41
doi: 10.1016/j.imlet.2013.03.004
Côté-Maurais G, Bernier J (2014) Silver and fullerene nanoparticles’ effect on interleukin-2-dependent proliferation of CD4 (+) T cells. Toxicol In Vitro 28(8):1474–1481
doi: 10.1016/j.tiv.2014.08.005
Li Y, Italiani P, Casals E, Valkenborg D, Mertens I, Baggerman G, Nelissen I, Puntes VF, Boraschi D (2016) Assessing the immunosafety of engineered nanoparticles with a novel in vitro model based on human primary monocytes. ACS Appl Mater Interfaces 8(42):28437–28447
doi: 10.1021/acsami.6b06278
Haase H, Fahmi A, Mahltig B (2014) Impact of silver nanoparticles and silver ions on innate immune cells. J Biomed Nanotechnol 10(6):1146–1156
doi: 10.1166/jbn.2014.1784
Directorate-General for Health and Consumers (European Commission) (2015) Guidance on the determination of potential health effects of nanomaterials used in medical devices. https://doi.org/10.2772/41391 . Available at: http://ec.europa.eu/health/scientific_committees/emerging/opinions/index_en.htm